Valneva SE (NASDAQ:VALN – Free Report) – HC Wainwright increased their Q3 2024 earnings per share estimates for Valneva in a research note issued to investors on Monday, July 22nd. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($0.46) for the quarter, up from their prior forecast of ($0.49). HC Wainwright has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for Valneva’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Valneva’s Q4 2024 earnings at ($0.46) EPS, FY2024 earnings at ($0.50) EPS and FY2026 earnings at ($0.76) EPS.
Valneva (NASDAQ:VALN – Get Free Report) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.12. The business had revenue of $35.56 million for the quarter, compared to analysts’ expectations of $95.80 million. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%.
Valneva Price Performance
Institutional Trading of Valneva
An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. raised its holdings in Valneva SE (NASDAQ:VALN – Free Report) by 2.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 354,361 shares of the company’s stock after buying an additional 9,361 shares during the quarter. General American Investors Co. Inc. owned about 0.51% of Valneva worth $2,831,000 at the end of the most recent reporting period. 11.39% of the stock is currently owned by hedge funds and other institutional investors.
Valneva Company Profile
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Read More
- Five stocks we like better than Valneva
- What Are Trending Stocks? Trending Stocks Explained
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Investing In Automotive Stocks
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.